Search results for "Decline"

showing 10 items of 261 documents

Bi-allelic JAM2 Variants Lead to Early-Onset Recessive Primary Familial Brain Calcification

2020

International audience; Primary familial brain calcification (PFBC) is a rare neurodegenerative disorder characterized by a combination of neurological, psychiatric, and cognitive decline associated with calcium deposition on brain imaging. To date, mutations in five genes have been linked to PFBC. However, more than 50% of individuals affected by PFBC have no molecular diagnosis. We report four unrelated families presenting with initial learning difficulties and seizures and later psychiatric symptoms, cerebellar ataxia, extrapyramidal signs, and extensive calcifications on brain imaging. Through a combination of homozygosity mapping and exome sequencing, we mapped this phenotype to chromo…

0301 basic medicineMaleCerebellumPathology[SDV]Life Sciences [q-bio]recessive brain calcificationMice0302 clinical medicineCognitive declineAge of OnsetChildGenetics (clinical)Exome sequencingComputingMilieux_MISCELLANEOUSBrain Diseasesprimary familial brain calcificationMalalties neurodegenerativesBrainFahr diseaseCalcinosisOCLNNeurodegenerative DiseasesHuman brainMiddle AgedPedigree[SDV] Life Sciences [q-bio]medicine.anatomical_structureKnockout mouseFemalemedicine.symptomAdultmedicine.medical_specialtyAdolescentGenes RecessiveNeuropathologyBiologyCalcificacióCalcification03 medical and health sciencesBasal Ganglia DiseasesReportGeneticsmedicineAnimalsHumansAllelesSLC20A2Cerebellar ataxiaknock out mouse modelmedicine.diseaseJAM2030104 developmental biologyFahr disease; familial idiopathic basal ganglia calcification; JAM2; JAM3; knock out mouse model; MYORG; OCLN; primary familial brain calcification; recessive brain calcification; SLC20A2familial idiopathic basal ganglia calcificationJAM3MYORGXenotropic and Polytropic Retrovirus ReceptorCell Adhesion Molecules030217 neurology & neurosurgeryCalcification
researchProduct

Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer's disease.

2020

Abstract The earliest hallmarks of sporadic Alzheimer's disease (sAD) are impaired glucose metabolism, chronic neuroinflammation, diminished synaptic plasticity and subsequent cognitive decline. The safest antidiabetic drug metformin has shown both glucose metabolism-improving and cognition-enhancing action in type 2 diabetes patients and diabetic model animals. However, metformin has not been previously studied in intracerebroventricular streptozocin (STZ)-induced model of sAD. Therefore, our aim was to assess the preventive action of metformin in sAD model-rats. Firstly, the actions of metformin (75 and 100 mg/kg) on cognitive functions and sociability were examined. Secondly, we wanted t…

0301 basic medicineMaleendocrine system diseasesNerve Tissue ProteinsType 2 diabetesPharmacologyGPI-Linked ProteinsNeuroprotectionStreptozocin03 medical and health sciencesGlycogen Synthase Kinase 30302 clinical medicineCognitionAlzheimer DiseaseMorris Water Maze TestMedicineAnimalsHypoglycemic AgentsCognitive declineRats WistarSocial BehaviorNeuroinflammationInjections IntraventricularPharmacologyGlucose Transporter Type 1Behavior AnimalGlucose Transporter Type 3business.industrydigestive oral and skin physiologyGlucose transporternutritional and metabolic diseasesBrainmedicine.diseaseMetforminMetforminAstrogliosisDisease Models Animal030104 developmental biologyGlucoseNeuroprotective AgentsSynaptic plasticityAcetylcholinesterasebusinessNeuroglia030217 neurology & neurosurgerymedicine.drugEuropean journal of pharmacology
researchProduct

Mild behavioral impairment in Parkinson's disease: Data from the Parkinson's disease cognitive impairment study (PACOS)

2019

Neuropsychiatric symptoms (NPS) have been frequently described in Parkinson's disease (PD), even in the earliest stages of the disease. Recently the construct of mild behavioral impairment (MBI) has been proposed as an at-risk state for incident cognitive decline and dementia. The aim of the present study is to evaluate the prevalence and associated factors of MBI in PD. Cross-sectional data from 429 consecutive PD patients enrolled in the PArkinson's disease COgnitive impairment Study (PACOS) were included in the study. All subjects underwent neuropsychological assessment, according to the MDS Level II criteria. NPS were evaluated with the Neuropsychiatric Inventory. Multivariate logistic …

0301 basic medicineMalemedicine.medical_specialtyParkinson's diseaseParkinson's diseaseMild behavioral impairmentNeuropsychiatric symptomDiseaseCognitive impairment; Mild behavioral impairment; Neuropsychiatric symptoms; Parkinson's disease; Prevalence; Neuroscience (all); Clinical Psychology; Geriatrics and Gerontology; Psychiatry and Mental HealthNeuropsychological TestsLogistic regressionSeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicinemedicinePrevalenceDementiaHumansCognitive DysfunctionNeuropsychological assessmentCognitive declineStage (cooking)Cognitive impairmentAgedNeuroscience (all)medicine.diagnostic_testbusiness.industryGeneral NeuroscienceParkinson DiseaseGeneral MedicineMiddle Agedmedicine.diseaseNeuropsychiatric symptomsClinical Psychology030104 developmental biologyCross-Sectional StudiesCognitive impairmentPsychiatry and Mental HealthFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgery
researchProduct

Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach

2021

Abstract Introduction Essential Tremor (ET) is increasingly recognized as a complex disorder with additional clinical signs other than tremor. It is still unknown whether a unique pathophysiologic or neurodegenerative process underlies progression and prognosis of the disease. The aim of the study was to identify ET phenotypes through a clinical-instrumental data-driven approach and to characterize possible patterns of neurodegeneration. Methods ET patients were categorized using spatio-temporal and kinematic variables related to mobility and dynamic stability processed by motion transducers. Differences between the identified groups in clinical-demographic variables, neuropsychological per…

0301 basic medicineRetinal degenerationMalemedicine.medical_specialtyHead tremorTimed up and go testRetina03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitation80 and overNeurologicMedicineHumansCognitive DysfunctionGait DisordersCognitive declineNeurodegenerationTomographyGait Disorders NeurologicAgedAged 80 and overEssential tremorOptical coherence tomographybusiness.industryNeuropsychologyCognitionNeurodegenerative Diseasesmedicine.diseaseAction tremorGait030104 developmental biologyNeurologyOptical CoherenceEssential tremorFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)Geriatrics and Gerontologybusiness030217 neurology & neurosurgeryTomography Optical Coherence
researchProduct

Environmental factors influencing the distribution and prevalence ofSchistosoma haematobiumin school attenders of ILembe and uThungulu Health Distric…

2017

Schistosoma haematobium infection is reported to facilitate the development of urogenital diseases. Its symptoms include haematuria, dysuria and tiredness, and it may cause cognitive decline in chi...

0301 basic medicineSchistosoma haematobiumbiologybusiness.industry030231 tropical medicineDistribution (economics)urologic and male genital diseasesbiology.organism_classificationUrogenital diseasesfemale genital diseases and pregnancy complications03 medical and health sciences030104 developmental biology0302 clinical medicineSchistosoma haematobium infectionEnvironmental healthparasitic diseasesImmunologyMedicineUrogenital SchistosomiasisDysuriaCognitive declinemedicine.symptombusinessKwazulu natalSouthern African Journal of Infectious Diseases
researchProduct

Dysregulation of C-X-C motif ligand 10 during aging and association with cognitive performance

2017

International audience; Chronic low-grade inflammation during aging (inflammaging) is associated with cognitive decline and neurodegeneration; however, the mechanisms underlying inflammaging are unclear. We studied a population (n = 361) of healthy young and old adults from the MyoAge cohort. Peripheral levels of C-X-C motif chemokine ligand 10 (CXCL10) was found to be higher in older adults, compared with young, and negatively associated with working memory performance. This coincided with an age-related reduction in blood DNA methylation at specific CpGs within the CXCL10 gene promoter. In vitro analysis supported the role of DNA methylation in regulating CXCL10 transcription. A polymorph…

0301 basic medicinegamma interferon inducible protein 10genomic DNAAlzheimerin tautiEpigenesis GeneticCohort StudiesCXCL10 geneCognitionsingle nucleotide polymorphismcognitive defectCognitive declineAged 80 and overCerebral Cortexeducation.field_of_studyprefrontal cortexDNA methylationGeneral NeuroscienceadultNeurodegenerationneurodegenerationta3141U937 CellsMethylationta3142Alzheimer's diseasecohort analysisDNA-metylaatioagedfemalepriority journalepigenetiikkaDNA methylationAlzheimer's diseaseAlzheimer diseasetranscription regulationAlzheimer’s diseasekognitiiviset taidotmedicine.medical_specialty[SDV.MHEP.AHA] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]in vitro studyAdolescentheredityPopulationBiologyArticleworking memoryYoung Adult03 medical and health sciencesCognitive agingpromoter regionmaleMemoryInternal medicineJournal Articlemedicine[SDV.MHEP.AHA]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]HumansCXCL10controlled studyEpigeneticshumanbrain levelNeurodegenerationeducationepigeneticscognitive aginghuman cellagingdisease associationmedicine.diseasemajor clinical studyInflammagingChemokine CXCL10gamma interferon inducible protein 10; genomic DNA adult; age; aged; aging; Alzheimer disease; Article; brain level; cognitive defect; cohort analysis; controlled study; CpG island; CXCL10 gene; disease association; DNA methylation; epigenetics; female; heredity; human; human cell; in vitro study; inflammation; major clinical study; male; prefrontal cortex; priority journal; promoter region; single nucleotide polymorphism; transcription regulation; working memory; Alzheimer's disease; Cognitive aging; DNA methylation; Epigenetics; Inflammaging; Neurodegeneration030104 developmental biologyEndocrinologyikääntyminenageinflammationNerve DegenerationCpG islandinflammagingNeurology (clinical)Geriatrics and GerontologyHeLa CellsDevelopmental BiologyNeurobiology of Aging
researchProduct

Association of interleukin-6 rs1800796 polymorphism with reduced cognitive performance in healthy older adults

2019

© 2018 Elsevier B.V. With increasing life expectancy, age-associated cognitive impairment is an escalating problem worldwide. Inflammation is one of the features that characterises cognitive decline and can stimulate neurodegeneration. Interleukin 6 (IL-6) is a cytokine frequently associated with a pro-inflammatory phenotype and increased levels have been associated with the pathogenesis of dementia. The rs1800796 polymorphism in the promoter region of IL-6 gene was previously shown to influence IL-6 expression and therefore we hypothesised this gene polymorphism would be associated with IL-6 plasma levels and cognitive performance of older adults. The present study investigated the associa…

0301 basic medicinekognitioAgingPhysiologyinterleukin 6ta311103 medical and health sciencesCognitive aging0302 clinical medicineSDG 3 - Good Health and Well-beingGeneticsmedicineDementiaEffects of sleep deprivation on cognitive performanceCognitive declineEpisodic memoryGenetics (clinical)InflammationIL-6tulehdusWorking memorybusiness.industryCambridge Neuropsychological Test Automated BatterysytokiinitCognitionta3142medicine.diseasers1800796030104 developmental biologyikääntyminen030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingGene polymorphismgeneettiset tekijätbusinessdementia
researchProduct

Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study

2020

Abstract Background Vascular risk factors (VRFs) may be associated with cognitive decline in early Parkinson’s disease (PD) but results are inconclusive. The identification of modifiable risk factors is relevant for prevention and treatment. Methods Parkinson’s disease (PD) patients of the PACOS cohort who underwent a baseline and follow-up neuropsychological evaluation were enrolled in the study. PD with Mild Cognitive Impairment (MCI) and dementia (PDD) were diagnosed according to the MDS criteria. A Baseline 1.5 T brain MRI was used to calculate the white matter lesions (WMLs) burden using the Wahlund visual scale. Laboratory data, presence of hypertension, diabetes and use of anti-hyper…

0301 basic medicinemedicine.medical_specialtyEpidemiologyNeuropsychological Testsbehavioral disciplines and activitiesWhite matter lesions03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyHumansMedicineDementiaCognitive DysfunctionLongitudinal StudiesRisk factorCognitive declineOriginal CommunicationFramingham Risk Scorebusiness.industryMild cognitive impairmentParkinson DiseaseEpidemiology Hypertension Mild cognitive impairment Parkinson’s disease Risk factors White matter lesions Humans Longitudinal Studies Neuropsychological Tests Risk Factors Cognitive Dysfunction Parkinson Disease White Mattermedicine.diseaseWhite MatterHyperintensitynervous system diseases030104 developmental biologyBlood pressureRisk factorsNeurologyHypertensionCohortParkinson’s diseaseNeurology (clinical)business030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Impact of supplementation with vitamins B 6 , B 12 , and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impair…

2021

Hyperhomocysteinemia is an independent predictor of the risk for cognitive decline and may be a result of low levels of vitamins B12 , B6 , and folate. Previous findings suggest that adequate intake of these vitamins may reduce homocysteine levels. This review aimed to assess the effects of treatment with vitamins B6, B12 , and/or folic acid in the homocysteine levels in patients with mild cognitive impairment (MCI). A systematic literature review was conducted in EMBASE, MEDLINE®, PsycINFO, and Cochrane Central Register of Controlled Trials. The research question was formulated using the Population, Intervention, Comparison, and Outcome (PICO) framework: in patients with MCI (P); what is t…

0301 basic medicinemedicine.medical_specialtyHyperhomocysteinemiaHomocysteineClinical BiochemistryPopulationBiochemistryGastroenterologylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineGeneticsMedicineVitamin B12Cognitive declineeducationMolecular Biologyeducation.field_of_studybusiness.industryCell Biologymedicine.disease030104 developmental biologychemistryDietary Reference Intake030220 oncology & carcinogenesisObservational studybusinessIUBMB Life
researchProduct

Is TGF-β1 a Biomarker of Huntington’s Disease Progression?

2021

Huntington’s disease (HD) is an autosomal dominant genetic disease that can be divided into preclinical and symptomatic stages. Due to the diverse HD phenotype, there is an urgent need to identify markers that would independently assess its severity. The aim of this study was to evaluate the use of plasma levels of TGF-β1 in the assessment of HD severity. One hundred HD patients and 40 healthy volunteers were included in the study. All HD patients underwent neurological and cognitive function assessment. TGF-β1 levels were determined in the plasma of all patients. The correlations between TGF-β1 levels and clinical profile and HD severity were also investigated. In symptomatic patients, cog…

0301 basic medicinemedicine.medical_specialtymarkersDiseaseGastroenterologyArticle03 medical and health sciences0302 clinical medicineDisease severityHuntington's diseaseInternal medicineTGF-β1medicineCognitive declineStage (cooking)business.industryRGeneral MedicinePlasma levelsHuntington diseasemedicine.disease030104 developmental biologyBiomarker (medicine)Medicinebusiness030217 neurology & neurosurgeryTransforming growth factorJournal of Clinical Medicine
researchProduct